Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...
In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...
Abstract: In recent years, there has been growing interest in the automatic generation of Multiple Choice Questions (MCQs), mainly to reduce the effort and time involved in manual question ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results